Target Price | $31.86 |
Price | $20.60 |
Potential |
54.65%
register free of charge
|
Number of Estimates | 7 |
7 Analysts have issued a price target Catalyst Pharmaceuticals, Inc. 2025 .
The average Catalyst Pharmaceuticals, Inc. target price is $31.86.
This is
54.65%
register free of charge
$38.00
84.47%
register free of charge
$28.00
35.92%
register free of charge
|
|
A rating was issued by 7 analysts: 7 Analysts recommend Catalyst Pharmaceuticals, Inc. to buy, 0 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Catalyst Pharmaceuticals, Inc. stock has an average upside potential 2025 of
54.65%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 398.20 | 482.90 |
85.90% | 21.27% | |
EBITDA Margin | 30.13% | 42.58% |
37.54% | 41.34% | |
Net Margin | 18.87% | 29.39% |
54.81% | 55.75% |
7 Analysts have issued a sales forecast Catalyst Pharmaceuticals, Inc. 2024 . The average Catalyst Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Catalyst Pharmaceuticals, Inc. EBITDA forecast 2024. The average Catalyst Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Catalyst Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2024. The average Catalyst Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | 0.63 | 1.19 |
16.00% | 88.89% | |
P/E | 17.31 | |
EV/Sales | 4.18 |
5 Analysts have issued a Catalyst Pharmaceuticals, Inc. forecast for earnings per share. The average Catalyst Pharmaceuticals, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Catalyst Pharmaceuticals, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Catalyst Pharmaceuticals, Inc....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.